• Something wrong with this record ?

Vancomycin and its crystalline degradation products released from bone grafts and different types of bone cement

E. Klapkova, M. Nescakova, P. Melichercik, D. Jahoda, K. Dunovska, J. Cepova, R. Prusa,

. 2020 ; 65 (3) : 475-482. [pub] 20191025

Language English Country United States

Document type Journal Article

Grant support
00064203 Ministry of Health, Czech Republic

Vancomycin is often used in orthopedic surgery as a local prophylaxis of bacterial infection. The aim of this work was to compare the release of vancomycin and its biologically inactive crystalline degradation products (CDP-1) during in vitro experiments from different types of local antibiotic delivery systems (bone grafts and bone cements). The concentrations of vancomycin and its crystalline degradation products were determined by high-performance liquid chromatography. Each experiment was performed in a phosphate buffer solution over 21 days. Morselized bone grafts, synthetic bone cements Palacos and Copal, and synthetic bone grafts were tested as local carriers of vancomycin. The highest concentration approximately 670 mg/L of vancomycin was released from synthetic bone grafts Actifuse. Even after 21 days, the concentration of vancomycin was still above the minimum inhibitory concentration (MIC). The maximum concentration of vancomycin released in two experiments with human bone grafts exceeded 600 mg/L during the first day and was still above MIC level 21 days later when the experiment was concluded. By comparing the synthetic bone cements Palacos and Copal, Copal had the average maximum concentration of only 32.4 mg/L and Palacos 35.7 mg/L. The concentration of vancomycin fell below the MIC for vancomycin-resistant Staphylococcus aureus (VRSA) on the seventh day with Palacos and the ninth day with Copal. This study showed the insufficient concentration of released vancomycin from synthetic bone cements at the end of the experiment. For improvement of local prophylaxis, it would be beneficial to increase the amount of vancomycin in bone cements.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027178
003      
CZ-PrNML
005      
20210105141543.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12223-019-00752-w $2 doi
035    __
$a (PubMed)31654320
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Klapkova, Eva $u Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. eva.klapkova@email.cz.
245    10
$a Vancomycin and its crystalline degradation products released from bone grafts and different types of bone cement / $c E. Klapkova, M. Nescakova, P. Melichercik, D. Jahoda, K. Dunovska, J. Cepova, R. Prusa,
520    9_
$a Vancomycin is often used in orthopedic surgery as a local prophylaxis of bacterial infection. The aim of this work was to compare the release of vancomycin and its biologically inactive crystalline degradation products (CDP-1) during in vitro experiments from different types of local antibiotic delivery systems (bone grafts and bone cements). The concentrations of vancomycin and its crystalline degradation products were determined by high-performance liquid chromatography. Each experiment was performed in a phosphate buffer solution over 21 days. Morselized bone grafts, synthetic bone cements Palacos and Copal, and synthetic bone grafts were tested as local carriers of vancomycin. The highest concentration approximately 670 mg/L of vancomycin was released from synthetic bone grafts Actifuse. Even after 21 days, the concentration of vancomycin was still above the minimum inhibitory concentration (MIC). The maximum concentration of vancomycin released in two experiments with human bone grafts exceeded 600 mg/L during the first day and was still above MIC level 21 days later when the experiment was concluded. By comparing the synthetic bone cements Palacos and Copal, Copal had the average maximum concentration of only 32.4 mg/L and Palacos 35.7 mg/L. The concentration of vancomycin fell below the MIC for vancomycin-resistant Staphylococcus aureus (VRSA) on the seventh day with Palacos and the ninth day with Copal. This study showed the insufficient concentration of released vancomycin from synthetic bone cements at the end of the experiment. For improvement of local prophylaxis, it would be beneficial to increase the amount of vancomycin in bone cements.
650    _2
$a antibakteriální látky $x analýza $x metabolismus $7 D000900
650    _2
$a kostní cementy $x analýza $7 D001843
650    _2
$a transplantace kostí $7 D016025
650    _2
$a vysokoúčinná kapalinová chromatografie $7 D002851
650    _2
$a lidé $7 D006801
650    _2
$a methicilin rezistentní Staphylococcus aureus $x účinky léků $7 D055624
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a vankomycin $x analýza $x metabolismus $7 D014640
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nescakova, Monika $u Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Melichercik, Pavel $u Department of Orthopaedics, Charles University, First Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Jahoda, David $u Department of Orthopaedics, Charles University, First Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Dunovska, Katerina $u Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Cepova, Jana $u Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Prusa, Richard $u Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
773    0_
$w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 65, č. 3 (2020), s. 475-482
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31654320 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210105141539 $b ABA008
999    __
$a ok $b bmc $g 1604158 $s 1117870
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 65 $c 3 $d 475-482 $e 20191025 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
GRA    __
$a 00064203 $p Ministry of Health, Czech Republic
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...